June 7, 2018
BioMarin bags $20 million in milestone payments
BioMarin Pharmaceutical has received $20 million in milestone payments from Pfizer Inc, it said Thursday.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: BioMarin
March 29, 2018
EMA accepts BioMarin’s Pegvaliase MAA for treatment of Phenylketonuria (PKU)
European Medicines Agency (EMA) has accepted BioMarin’s submission of a Marketing Authorization Application (MAA) for pegvaliase for the treatment of…
December 20, 2017
BioMarin doses first patient in global GENEr8-1 Phase 3 study
BioMarin Pharmaceutical has dosed the first patient in the global GENEr8-1 Phase 3 study with the 6e13 vg/kg dose for…
August 7, 2017
BioMarin in offering of $450 M
BioMarin Pharmaceutical issued a press release on Mondayan in which it announced underwritten offering of $450 million of senior subordinated convertible notes due 2024. BioMarin has also granted the underwriters a 13-day option to buy up to an additional $50 million aggregate principal amount of Notes.
June 1, 2017
BioMarin cleared in EU for TPP1 deficiency treatment
BioMarin Pharmaceuticalsaid today that it got from the European Commission (EC) a grant for Brineura (cerliponase alfa), the first treatment approved in the European Union (EU) for tripeptidyl peptidase 1 (TPP1) deficiency.
April 13, 2017
BioMarin settles with Par Pharmaceutical on patent for tablets and powder
BioMarin Pharmaceutical and Par Pharmaceutical have entered into a settlement agreement that resolves patent litigation in the United States (U.S.) related to BioMarin’s Kuvan 100mg oral tablets and powder for oral solution in 100mg packets.
February 1, 2017
Biomarin’s hemophilia drug nets PRIME status in Europe
BioMarin Pharmaceutical’s treatment for hemophilia has been accepted for PRIME (Priority Medicines) scheme from the European Medicines Agency (EMA).